Modality
ASO
MOA
IL-23i
Target
BCL-2
Pathway
JAK/STAT
OCD
Development Pipeline
Preclinical
Dec 2017
→ Aug 2025
PreclinicalCurrent
NCT07132178
1,443 pts·OCD
2017-12→2025-08·Recruiting
1,443 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-128mo agoInterim· OCD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2025-08-12 · 8mo ago
OCD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07132178 | Preclinical | OCD | Recruiting | 1443 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 |